ATE512957T1 - Hemmer der akt aktivität - Google Patents
Hemmer der akt aktivitätInfo
- Publication number
- ATE512957T1 ATE512957T1 AT04760294T AT04760294T ATE512957T1 AT E512957 T1 ATE512957 T1 AT E512957T1 AT 04760294 T AT04760294 T AT 04760294T AT 04760294 T AT04760294 T AT 04760294T AT E512957 T1 ATE512957 T1 AT E512957T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- activity inhibitor
- act activity
- directed
- act
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100030011 Endoribonuclease Human genes 0.000 abstract 1
- 101710199605 Endoribonuclease Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46526003P | 2003-04-24 | 2003-04-24 | |
| PCT/US2004/012188 WO2004096131A2 (en) | 2003-04-24 | 2004-04-20 | Inhibitors of akt activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE512957T1 true ATE512957T1 (de) | 2011-07-15 |
Family
ID=33418212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04760294T ATE512957T1 (de) | 2003-04-24 | 2004-04-20 | Hemmer der akt aktivität |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7579355B2 (de) |
| EP (1) | EP1622616B1 (de) |
| JP (1) | JP4616831B2 (de) |
| CN (1) | CN1809354A (de) |
| AT (1) | ATE512957T1 (de) |
| AU (1) | AU2004233828B2 (de) |
| CA (1) | CA2522431A1 (de) |
| WO (1) | WO2004096131A2 (de) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CN1942470A (zh) | 2004-04-09 | 2007-04-04 | 默克公司 | Akt活性抑制剂 |
| CA2561311A1 (en) | 2004-04-09 | 2005-10-27 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| US7544677B2 (en) * | 2004-08-23 | 2009-06-09 | Merck & Co., Inc. | Inhibitors of Akt activity |
| AU2005283326B2 (en) * | 2004-09-13 | 2011-07-21 | Ono Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| EP1812439B2 (de) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinaseinhibitoren |
| JP4931823B2 (ja) | 2004-10-18 | 2012-05-16 | アムジエン・インコーポレーテツド | チアジアゾール化合物及び使用方法 |
| EP1746099A1 (de) * | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 Inhibitoren |
| KR20070091038A (ko) * | 2004-12-24 | 2007-09-06 | 프로시디온 리미티드 | G-단백질 결합 수용체(gpr116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도 |
| JP2008535915A (ja) | 2005-04-12 | 2008-09-04 | メルク エンド カムパニー インコーポレーテッド | Akt活性の阻害剤 |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| WO2006135627A2 (en) | 2005-06-10 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of akt activity |
| BRPI0614262A2 (pt) | 2005-08-02 | 2011-03-15 | Lexicon Pharmaceuticals Inc | aril piridinas e métodos para uso das mesmas |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2007087246A2 (en) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Jak2 tyrosine kinase inhibition |
| RU2008140144A (ru) | 2006-03-10 | 2010-04-20 | Оно Фармасьютикал Ко., Лтд. (Jp) | Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента |
| CA2646316C (en) | 2006-03-15 | 2016-05-24 | Theralogics, Inc. | Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| EP2120951A4 (de) * | 2006-12-06 | 2012-02-15 | Merck Sharp & Dohme | Hemmer der akt-aktivität |
| US7919504B2 (en) | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| CA2694058C (en) | 2007-08-14 | 2016-06-07 | Bayer Schering Pharma Aktiengesellschaft | Fused bicyclic pyrimidines |
| CA2695251C (en) * | 2007-08-14 | 2016-06-21 | Bayer Schering Pharma Aktiengesellschaft | Fused imidazoles for cancer treatment |
| EP2062893A1 (de) * | 2007-10-18 | 2009-05-27 | Bayer Schering Pharma AG | Fusionierte Imidazole zur Behandlung von Krebs |
| US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| US8207169B2 (en) * | 2008-06-03 | 2012-06-26 | Msd K.K. | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D |
| JP2011522047A (ja) * | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
| JP5609022B2 (ja) | 2008-06-23 | 2014-10-22 | 住友化学株式会社 | 金属錯体の残基を含む高分子化合物及びそれを用いた素子 |
| WO2010006792A1 (de) * | 2008-07-16 | 2010-01-21 | Bitop Ag | Synthese von zyklischen amidinen |
| JP2012513411A (ja) * | 2008-12-22 | 2012-06-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Aktの選択的阻害剤およびその使用方法 |
| EP2393827B1 (de) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Neue prodrugs von steroiden cyp17-inhibitoren/antiandrogenen |
| US20130310362A1 (en) | 2009-02-13 | 2013-11-21 | Bayer Pharma Aktiegesellschaft | Fused pyrimidines |
| US8957064B2 (en) | 2009-02-13 | 2015-02-17 | Bayer Intellectual Property Gmbh | Fused pyrimidines |
| WO2010104705A1 (en) | 2009-03-12 | 2010-09-16 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2413932A4 (de) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Hemmer der akt-aktivität |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制 |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| MX336865B (es) | 2011-04-07 | 2016-02-04 | Bayer Pharma AG | Imidazopiridazinas como inhibidores de quinasa akt. |
| EP2770987B1 (de) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Neue verbindungen als erk-hemmer |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013096093A1 (en) * | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Compounds as dgat-1 inhibitors |
| EP3919620A1 (de) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Zusammensetzungen mit kurzer interferierender nukleinsäure (sina) |
| CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| SMT201700595T1 (it) | 2012-11-28 | 2018-03-08 | Merck Sharp & Dohme | Composizioni e metodi per trattare il cancro |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
| KR20160058774A (ko) | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015051252A1 (en) * | 2013-10-03 | 2015-04-09 | Duke University | Compositions and methods for treating cancer with jak2 activity |
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3392244A1 (de) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamine als lsd1-inhibitoren |
| CN105294571B (zh) * | 2014-07-03 | 2019-04-23 | 浙江九洲药业股份有限公司 | 一种依鲁替尼中间体及其制备方法和用途 |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| DK3334709T3 (da) | 2015-08-12 | 2025-02-03 | Incyte Holdings Corp | Salte af en lsd1-hæmmer |
| CA3021678A1 (en) | 2016-04-22 | 2017-10-26 | Incyte Corporation | Formulations of an lsd1 inhibitor |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | 抗sirpアルファ抗体 |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3706742B1 (de) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN111377873B (zh) * | 2018-12-28 | 2023-03-28 | 四川科伦博泰生物医药股份有限公司 | 氨基嘧啶化合物及其制备方法和用途 |
| CN113166119B (zh) * | 2018-12-28 | 2024-01-05 | 四川科伦博泰生物医药股份有限公司 | 取代芳基化合物及其制备方法和用途 |
| CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| EP4076460B1 (de) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs |
| EP4076459B1 (de) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| ES3022307T3 (en) | 2019-12-17 | 2025-05-28 | Merck Sharp & Dohme Llc | Prmt5 inhibitors |
| ES3074517T3 (en) | 2019-12-17 | 2026-07-21 | Merck Sharp & Dohme Llc | 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease |
| DE212025000115U1 (de) | 2024-07-30 | 2026-06-18 | Sairopa B.V. | Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung |
| KR20260032422A (ko) * | 2024-08-30 | 2026-03-09 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506219A (en) * | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
| NZ230121A (en) | 1988-08-29 | 1993-08-26 | Squibb & Sons Inc | Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels |
| US5594011A (en) * | 1994-11-10 | 1997-01-14 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5703100A (en) | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| WO1996023769A2 (en) | 1995-02-02 | 1996-08-08 | Smithkline Beecham Plc | Heterocyclic compounds possessing 5ht2c receptor antagonist activity |
| US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US20020127214A1 (en) * | 1995-11-16 | 2002-09-12 | Hemmings Brian Arthur | RAC-protein kinase as therapeutic agent or in diagnostics |
| JP2000502097A (ja) | 1995-12-20 | 2000-02-22 | メディカル、リサーチ、カウンシル | タンパク質合成の制御、および作用薬のスクリーニング法 |
| US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| JP2004527531A (ja) | 2001-04-10 | 2004-09-09 | メルク エンド カムパニー インコーポレーテッド | 癌を治療する方法 |
| WO2002083140A1 (en) * | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| US6960584B2 (en) * | 2001-04-10 | 2005-11-01 | Merck & Co., Inc. | Inhibitors of Akt activity |
| US20040116433A1 (en) * | 2002-04-08 | 2004-06-17 | Owens Andrew Pate | Inhibitors of akt activity |
| JP4361276B2 (ja) | 2001-04-10 | 2009-11-11 | メルク エンド カムパニー インコーポレーテッド | Akt活性の阻害物質 |
| US20050188294A1 (en) * | 2004-02-23 | 2005-08-25 | Kuchinsky Allan J. | Systems, tools and methods for constructing interactive biological diagrams |
| JP4451136B2 (ja) * | 2002-04-08 | 2010-04-14 | メルク エンド カムパニー インコーポレーテッド | Akt活性阻害薬 |
| AU2003226301A1 (en) * | 2002-04-08 | 2003-10-20 | Merck And Co., Inc. | Method of treating cancer |
| WO2003086404A1 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
| CA2480800C (en) * | 2002-04-08 | 2008-09-23 | Mark T. Bilodeau | Inhibitors of akt activity |
| WO2003086279A2 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| AU2003284981B2 (en) | 2002-10-30 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| DE602004026047D1 (de) * | 2003-04-24 | 2010-04-29 | Merck Sharp & Dohme | Hemmer der akt aktivität |
| US7414055B2 (en) * | 2003-04-24 | 2008-08-19 | Merck & Co., Inc. | Inhibitors of Akt activity |
-
2004
- 2004-04-20 AU AU2004233828A patent/AU2004233828B2/en not_active Ceased
- 2004-04-20 CA CA002522431A patent/CA2522431A1/en not_active Abandoned
- 2004-04-20 AT AT04760294T patent/ATE512957T1/de not_active IP Right Cessation
- 2004-04-20 JP JP2006513160A patent/JP4616831B2/ja not_active Expired - Fee Related
- 2004-04-20 WO PCT/US2004/012188 patent/WO2004096131A2/en not_active Ceased
- 2004-04-20 US US10/554,001 patent/US7579355B2/en not_active Expired - Fee Related
- 2004-04-20 EP EP04760294A patent/EP1622616B1/de not_active Expired - Lifetime
- 2004-04-20 CN CNA200480017118XA patent/CN1809354A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1622616A4 (de) | 2010-04-21 |
| EP1622616B1 (de) | 2011-06-15 |
| US20070043001A1 (en) | 2007-02-22 |
| CA2522431A1 (en) | 2004-11-11 |
| US7579355B2 (en) | 2009-08-25 |
| CN1809354A (zh) | 2006-07-26 |
| AU2004233828A1 (en) | 2004-11-11 |
| AU2004233828B2 (en) | 2009-05-28 |
| JP2006524696A (ja) | 2006-11-02 |
| EP1622616A2 (de) | 2006-02-08 |
| JP4616831B2 (ja) | 2011-01-19 |
| WO2004096131A2 (en) | 2004-11-11 |
| WO2004096131A3 (en) | 2005-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE446752T1 (de) | Hemmer der akt aktivität | |
| ATE461179T1 (de) | Hemmer der akt aktivität | |
| EP1622616A4 (de) | Hemmer der akt aktivität | |
| ATE400274T1 (de) | Hemmstoffe der akt aktivität | |
| ATE503483T1 (de) | Hemmer der akt aktivität | |
| ATE499364T1 (de) | Hemmer der akt aktivität | |
| WO2003086279A3 (en) | Inhibitors of akt activity | |
| WO2004096130A3 (en) | Inhibitors of akt activity | |
| WO2006036395A3 (en) | Inhibitors of akt activity | |
| CA2480800A1 (en) | Inhibitors of akt activity | |
| MXPA05013349A (es) | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| MXPA03010961A (es) | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. | |
| ATE419253T1 (de) | Inhibitoren von thienopyridin- und furopyridinkinase | |
| IL178675A0 (en) | Monocyclic heterocycles as kinase inhibitors | |
| DE60214703D1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
| MXPA05011296A (es) | Conjugados de fosfonato inhibidores de la cinasa. | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| MXPA05013076A (es) | Compuestos de isoindolina-1-ona como inhibidores de cinasa. | |
| WO2004030620A3 (en) | Novel tyrosine kinase inhibitors | |
| MXPA05009151A (es) | Inhibidores de cinasa heterociclica. | |
| SE0302232D0 (sv) | Novel Compounds | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| ATE507218T1 (de) | Benzodiazepin-derivate als rock-kinasen hemmer | |
| DE50311665D1 (de) | Guanidinophenylalanin-verbindungen als urokinase-inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |